MA45493A - Inhibiteurs d'entrée de hcmv. - Google Patents

Inhibiteurs d'entrée de hcmv.

Info

Publication number
MA45493A
MA45493A MA045493A MA45493A MA45493A MA 45493 A MA45493 A MA 45493A MA 045493 A MA045493 A MA 045493A MA 45493 A MA45493 A MA 45493A MA 45493 A MA45493 A MA 45493A
Authority
MA
Morocco
Prior art keywords
hcmc
entry inhibitors
inhibitors
entry
hcmc entry
Prior art date
Application number
MA045493A
Other languages
English (en)
Inventor
Barbara Adler
Sampaio Kerstin Laib
Christian Sinzger
Cora Stegmann
Original Assignee
Aicuris Anti Infective Cures Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of MA45493A publication Critical patent/MA45493A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
MA045493A 2016-06-27 Inhibiteurs d'entrée de hcmv. MA45493A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16176520 2016-06-27

Publications (1)

Publication Number Publication Date
MA45493A true MA45493A (fr) 2019-05-01

Family

ID=56289338

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045493A MA45493A (fr) 2016-06-27 Inhibiteurs d'entrée de hcmv.

Country Status (6)

Country Link
US (2) US11390661B2 (fr)
EP (1) EP3474887A1 (fr)
AR (1) AR108890A1 (fr)
CA (1) CA3028859A1 (fr)
MA (1) MA45493A (fr)
WO (1) WO2018002081A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
WO2021055367A2 (fr) * 2019-09-17 2021-03-25 The Board Of Trustees Of The University Of Illinois Récepteurs modifiés pour le cytomégalovirus humain et leurs utilisations
WO2022013304A1 (fr) 2020-07-14 2022-01-20 Aicuris Gmbh & Co. Kg POLYPEPTIDES PDGFRα EN TANT QUE RÉCEPTEURS LEURRES VIRAUX
WO2022178415A1 (fr) * 2021-02-22 2022-08-25 Genentech, Inc. Procédés de modulation d'interactions de surface de cellule hôte avec des herpèsvirus

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
JP2001500015A (ja) 1996-09-06 2001-01-09 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6667173B2 (en) * 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
CN1628126A (zh) 2001-08-30 2005-06-15 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
DK2298278T3 (en) 2002-06-07 2016-02-01 Dyax Corp Prevention and reduction of blood loss and inflammatory response
CA2525969A1 (fr) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Proteines hybrides a intron et procede d'identification et d'utilisation de celles-ci
WO2005040229A2 (fr) 2003-10-24 2005-05-06 Avidia, Inc. Multimeres et monomeres comprenant des domaines de recepteur de lipoproteines de basse densite de classe a et egf
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
JPWO2005087269A1 (ja) * 2004-03-16 2008-01-24 株式会社ディナベック研究所 腫瘍増殖を抑制する方法
US8278262B2 (en) 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
PT2100618E (pt) * 2005-06-17 2014-04-07 Philadelphia Health & Educatio Um anticorpo anti-pdgfr-alfa para o tratamento de cancro ósseo metastático
WO2009021150A2 (fr) 2007-08-08 2009-02-12 California Pacific Medical Center Le récepteur du facteur de croissance dérivés des plaquettes tolère l'infectiosité du cytomégalovirus
ATE527353T1 (de) 2007-12-19 2011-10-15 Affibody Ab Pdgf-bindendes polypeptid aus protein a
CN107011425B (zh) 2008-11-03 2021-01-01 分子组合公司 抑制vegf-a受体相互作用的结合蛋白
EP2470556B1 (fr) 2009-08-27 2018-05-30 Covagen AG Composés de liaison à il-17 et leurs utilisations médicales
WO2011053798A2 (fr) * 2009-10-30 2011-05-05 The Administrators Of The Tulane Educational Fund Compositions peptidiques et procédés d'inhibition d'une infection par un virus de l'herpès
CN102753568B (zh) 2009-12-14 2014-08-20 塞尔蛋白质股份有限公司 用于识别具有结合配体能力的异源多聚体修饰的泛素蛋白质的方法
US8986951B2 (en) 2010-06-08 2015-03-24 Pieris Ag Tear lipocalin in muteins binding IL-4 R alpha
US9884910B2 (en) * 2012-04-24 2018-02-06 Thrombogenics Nv Anti-PDGF-C antibodies

Also Published As

Publication number Publication date
US11390661B2 (en) 2022-07-19
EP3474887A1 (fr) 2019-05-01
AR108890A1 (es) 2018-10-10
US20190161532A1 (en) 2019-05-30
US20210380664A1 (en) 2021-12-09
WO2018002081A1 (fr) 2018-01-04
CA3028859A1 (fr) 2018-01-04

Similar Documents

Publication Publication Date Title
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA54550A (fr) Inhibiteurs de kif18a
FR3059894B1 (fr) Pare-visage
DK3442972T3 (da) Bromdomænehæmmere
JP1640204S (ja) フェンダー
DK3681884T3 (da) Rad51-inhibitorer
MA52812A (fr) Inhibiteurs de sarm1
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3630744T3 (da) Pyrazol-magl-inhibitorer
MA49006A (fr) Inhibiteurs d'ip6k
DK3601785T3 (da) Belægning
MA52813A (fr) Inhibiteurs de sarm1
MA46889A (fr) Inhibiteurs de gsk-3
DK3481826T3 (da) Tyrosinkinaseinhibitorer
DK3599479T3 (da) Projektildetektering
DK3710457T3 (da) Immunproteasomhæmmere
DE102018108987A8 (de) Glättwerkzeug
DK3535461T3 (da) Sprængningsbeskyttelsesvæg
MA46888A (fr) Inhibiteurs de gsk-3
MA45493A (fr) Inhibiteurs d'entrée de hcmv.
ES1225190Y (es) Conjunto de ducha
DK3720840T3 (da) Cathepsinhæmmere
DK3701099T3 (da) Vægsystem
ES2966887T3 (es) Soluciones de conservación
MA54235A (fr) Hydrocyclone